Nepal seeks to procure Coronavirus vaccine from India to vaccinate around 20% of population

Nepal will pay for the vaccines.

The Nepal government has written to the Indian government, requesting for procurement of Covid-19 vaccine to inoculate around 20 per cent of the Nepali population. The Ministry of Foreign Affairs recently wrote to the Indian government, requesting for the supply of the vaccines that would suffice the need for the 20 per cent of the population.

Last week, Nepali Ambassador to India, Nilamber Acharya also held meeting with senior officials of Pune-based Serum Institute of India (SII), the largest vaccine manufacturer in the world that is also producing Covid vaccine developed by Oxford University.

To get the vaccines at the earliest, the Nepal government has requested India to buy vaccines for 20 per cent Nepalis, according to a news report published in Kathmandu Post on Wednesday.

At least two vaccine candidates including Oxford's AstraZeneca and domestically developed candidate Bharat Biotech's vaccine are in the final stages of a third phase trial in India.

India is the world's largest producer of vaccines.

In the first phase, the Nepal government is preparing to use the vaccines for frontline health workers, security personnel and senior citizens.

"Around 15 vaccine candidates of different countries and companies are in third phase trials," Shyam Raj Upreti, coordinator of Covid-19 Vaccine Advisory Committee, told the Post.

"The government has written letters to most of the countries for help and to the individual companies to procure the vaccines."

Last month the government sent diplomatic notes to India, China, Russia, the United Kingdom and the United States, countries whose vaccines against the coronavirus have either completed the third phase trials or are near their completion, for early availability in Nepal.

The government has estimated that vaccinating 52 per cent of the population would cost Rs 48 billion.

Of Nepal's total population, those below 15 will not be vaccinated as vaccines being trialled have not been tested on people below this age.

Of the remaining 72 per cent of the population, who are above 15 years, 20 per cent will be vaccinated with jabs provided by the COVAX programme. COVAX is a collaboration, with more than two-thirds of the world engaged, that has the world's largest and most diverse portfolio of potential Covid-19 vaccines. It is co-led by Gavi, the global vaccine alliance, and the World Health Organization.

Also Read: Chinese Coronavirus vaccine shows 79% effectiveness in late-stage trial

According to Upreti, the World Health Organization has asked the government to prepare for the rollout of Covid-19 vaccines under COVAX programmes in the second trimester of 2021.

Along with writing letters to the countries and companies manufacturing the vaccines, authorities are also doing a necessary homework-cost assessment of vaccines, supply system, storage facilities and removing legal hurdles.

 

 Source: IANS

A. Gayatri

Related Tags

Like and Share

Like us on Facebook or follow us on Twitter for more updates.


Download Our App